Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nab-paclitaxel + sargramostim
- Development stage
- Phase 2
- Lead developer
- University of Washington
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Subcutaneous
01
Overview
This combination therapy consists of nab-paclitaxel (Abraxane), an albumin-bound nanoparticle formulation of the taxane chemotherapy agent paclitaxel, and sargramostim (Leukine), a recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF). Nab-paclitaxel works by stabilizing microtubules, thereby inhibiting cell division and inducing apoptosis. Sargramostim is an immunomodulator that stimulates the production and activation of macrophages and dendritic cells, potentially enhancing the anti-tumor immune response. This specific chemoimmunotherapy regimen was evaluated by the University of Washington in a Phase II trial for patients with platinum-resistant or refractory epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- Other names
- paclitaxel albumin-stabilized nanoparticle formulationprotein-bound paclitaxelsargramostimGM-CSFgranulocyte-macrophage colony-stimulating factor
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on nab-paclitaxel + sargramostim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nab-paclitaxel + sargramostim.